Pfizer Debt to Equity Ratio 1986-2025 | PFE
Current and historical debt to equity ratio values for Pfizer (PFE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Pfizer debt/equity for the three months ending September 30, 2025 was 0.31.
| Pfizer Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2025-09-30 |
$115.64B |
$93.10B |
1.24 |
| 2025-06-30 |
$117.08B |
$89.01B |
1.32 |
| 2025-03-31 |
$117.39B |
$90.64B |
1.30 |
| 2024-12-31 |
$124.90B |
$88.50B |
1.41 |
| 2024-09-30 |
$126.92B |
$92.56B |
1.37 |
| 2024-06-30 |
$128.22B |
$87.98B |
1.46 |
| 2024-03-31 |
$128.54B |
$92.56B |
1.39 |
| 2023-12-31 |
$137.21B |
$89.29B |
1.54 |
| 2023-09-30 |
$117.82B |
$97.20B |
1.21 |
| 2023-06-30 |
$120.88B |
$99.29B |
1.22 |
| 2023-03-31 |
$94.38B |
$101.24B |
0.93 |
| 2022-12-31 |
$101.29B |
$95.92B |
1.06 |
| 2022-09-30 |
$102.46B |
$92.89B |
1.10 |
| 2022-06-30 |
$107.82B |
$87.47B |
1.23 |
| 2022-03-31 |
$101.16B |
$82.69B |
1.22 |
| 2021-12-31 |
$104.01B |
$77.46B |
1.34 |
| 2021-09-30 |
$103.22B |
$75.97B |
1.36 |
| 2021-06-30 |
$99.61B |
$70.32B |
1.42 |
| 2021-03-31 |
$89.95B |
$68.87B |
1.31 |
| 2020-12-31 |
$90.76B |
$63.47B |
1.43 |
| 2020-09-30 |
$113.49B |
$65.50B |
1.73 |
| 2020-06-30 |
$113.37B |
$64.56B |
1.76 |
| 2020-03-31 |
$101.00B |
$65.34B |
1.55 |
| 2019-12-31 |
$104.15B |
$63.45B |
1.64 |
| 2019-09-30 |
$105.05B |
$65.40B |
1.61 |
| 2019-06-30 |
$96.27B |
$59.92B |
1.61 |
| 2019-03-31 |
$96.26B |
$59.16B |
1.63 |
| 2018-12-31 |
$95.66B |
$63.76B |
1.50 |
| 2018-09-30 |
$96.17B |
$71.66B |
1.34 |
| 2018-06-30 |
$94.86B |
$70.12B |
1.35 |
| 2018-03-31 |
$94.07B |
$70.54B |
1.33 |
| 2017-12-31 |
$100.14B |
$71.66B |
1.40 |
| 2017-09-30 |
$111.04B |
$61.11B |
1.82 |
| 2017-06-30 |
$109.86B |
$58.69B |
1.87 |
| 2017-03-31 |
$110.04B |
$58.75B |
1.87 |
| 2016-12-31 |
$111.78B |
$59.84B |
1.87 |
| 2016-09-30 |
$114.83B |
$63.60B |
1.81 |
| 2016-06-30 |
$107.59B |
$63.07B |
1.71 |
| 2016-03-31 |
$99.58B |
$63.35B |
1.57 |
| 2015-12-31 |
$102.38B |
$65.00B |
1.58 |
| 2015-09-30 |
$103.74B |
$67.12B |
1.55 |
| 2015-06-30 |
$93.70B |
$67.18B |
1.40 |
| 2015-03-31 |
$93.05B |
$67.59B |
1.38 |
| 2014-12-31 |
$95.94B |
$71.62B |
1.34 |
| 2014-09-30 |
$93.06B |
$78.31B |
1.19 |
| 2014-06-30 |
$95.66B |
$76.96B |
1.24 |
| 2014-03-31 |
$93.74B |
$78.07B |
1.20 |
| 2013-12-31 |
$95.48B |
$76.62B |
1.25 |
| 2013-09-30 |
$97.17B |
$78.35B |
1.24 |
| 2013-06-30 |
$100.36B |
$78.98B |
1.27 |
| 2013-03-31 |
$104.57B |
$82.83B |
1.26 |
| 2012-12-31 |
$104.12B |
$81.68B |
1.28 |
| 2012-09-30 |
$100.49B |
$82.12B |
1.22 |
| 2012-06-30 |
$102.88B |
$79.96B |
1.29 |
| 2012-03-31 |
$102.01B |
$83.68B |
1.22 |
| 2011-12-31 |
$105.38B |
$82.62B |
1.28 |
| 2011-09-30 |
$105.60B |
$90.53B |
1.17 |
| 2011-06-30 |
$106.94B |
$88.96B |
1.20 |
| 2011-03-31 |
$104.42B |
$90.53B |
1.15 |
| 2010-12-31 |
$106.75B |
$88.27B |
1.21 |
| 2010-09-30 |
$103.35B |
$88.07B |
1.17 |
| 2010-06-30 |
$104.19B |
$86.88B |
1.20 |
| 2010-03-31 |
$105.03B |
$90.08B |
1.17 |
| 2009-12-31 |
$122.50B |
$90.45B |
1.35 |
| 2009-09-30 |
$75.04B |
$66.25B |
1.13 |
| 2009-06-30 |
$76.10B |
$63.24B |
1.20 |
| 2009-03-31 |
$62.49B |
$60.44B |
1.03 |
| 2008-12-31 |
$53.41B |
$57.74B |
0.93 |
| 2008-09-30 |
$47.91B |
$67.34B |
0.71 |
| 2008-06-30 |
$49.95B |
$66.57B |
0.75 |
| 2008-03-31 |
$51.13B |
$67.42B |
0.76 |
| 2007-12-31 |
$50.26B |
$65.01B |
0.77 |
| 2007-09-30 |
$42.42B |
$66.61B |
0.64 |
| 2007-06-30 |
$42.31B |
$68.09B |
0.62 |
| 2007-03-31 |
$38.00B |
$72.49B |
0.52 |
| 2006-12-31 |
$44.19B |
$71.36B |
0.62 |
| 2006-09-30 |
$38.87B |
$69.71B |
0.56 |
| 2006-06-30 |
$43.06B |
$68.49B |
0.63 |
| 2006-03-31 |
$43.35B |
$69.61B |
0.62 |
| 2005-12-31 |
$51.21B |
$65.76B |
0.78 |
| 2005-09-30 |
$43.54B |
$66.81B |
0.65 |
| 2005-06-30 |
$47.00B |
$65.33B |
0.72 |
| 2005-03-31 |
$55.40B |
$67.53B |
0.82 |
| 2004-12-31 |
$54.80B |
$68.28B |
0.80 |
| 2004-09-30 |
$53.85B |
$68.38B |
0.79 |
| 2004-06-30 |
$53.26B |
$66.71B |
0.80 |
| 2004-03-31 |
$53.24B |
$69.05B |
0.77 |
| 2003-12-31 |
$51.40B |
$65.38B |
0.79 |
| 2003-09-30 |
$51.53B |
$68.53B |
0.75 |
| 2003-06-30 |
$53.98B |
$70.28B |
0.77 |
| 2003-03-31 |
$28.09B |
$24.84B |
1.13 |
| 2002-12-31 |
$26.41B |
$19.95B |
1.32 |
| 2002-09-30 |
$25.92B |
$18.95B |
1.37 |
| 2002-06-30 |
$23.74B |
$18.83B |
1.26 |
| 2002-03-31 |
$21.64B |
$19.67B |
1.10 |
| 2001-12-31 |
$20.86B |
$18.29B |
1.14 |
| 2001-09-30 |
$19.91B |
$18.90B |
1.05 |
| 2001-06-30 |
$19.13B |
$17.82B |
1.07 |
| 2001-03-31 |
$17.40B |
$17.75B |
0.98 |
| 2000-12-31 |
$17.43B |
$16.08B |
1.08 |
| 2000-09-30 |
$17.32B |
$16.17B |
1.07 |
| 2000-06-30 |
$17.07B |
$14.97B |
1.14 |
| 2000-03-31 |
$10.04B |
$10.19B |
0.99 |
| 1999-12-31 |
$11.69B |
$8.89B |
1.32 |
| 1999-09-30 |
$11.45B |
$8.79B |
1.30 |
| 1999-06-30 |
$10.99B |
$8.65B |
1.27 |
| 1999-03-31 |
$9.98B |
$9.05B |
1.10 |
| 1998-12-31 |
$9.49B |
$8.81B |
1.08 |
| 1998-09-30 |
$9.53B |
$8.65B |
1.10 |
| 1998-06-30 |
$8.20B |
$8.31B |
0.99 |
| 1998-03-31 |
$7.77B |
$8.19B |
0.95 |
| 1997-12-31 |
$7.40B |
$7.93B |
0.93 |
| 1997-09-30 |
$7.94B |
$7.41B |
1.07 |
| 1997-06-30 |
$8.56B |
$7.17B |
1.19 |
| 1997-03-31 |
$7.90B |
$7.15B |
1.11 |
| 1996-12-31 |
$7.71B |
$6.95B |
1.11 |
| 1996-09-30 |
$8.05B |
$6.57B |
1.23 |
| 1996-06-30 |
$7.64B |
$5.98B |
1.28 |
| 1996-03-31 |
$7.29B |
$5.89B |
1.24 |
| 1995-12-31 |
$7.22B |
$5.51B |
1.31 |
| 1995-09-30 |
$7.54B |
$5.28B |
1.43 |
| 1995-06-30 |
$8.12B |
$4.83B |
1.68 |
| 1995-03-31 |
$7.82B |
$4.70B |
1.67 |
| 1994-12-31 |
$6.78B |
$4.32B |
1.57 |
| 1994-09-30 |
$6.25B |
$4.15B |
1.50 |
| 1994-06-30 |
$6.32B |
$3.75B |
1.69 |
| 1994-03-31 |
$5.77B |
$3.84B |
1.50 |
| 1993-12-31 |
$5.47B |
$3.87B |
1.41 |
| 1993-09-30 |
$6.02B |
$3.82B |
1.58 |
| 1993-06-30 |
$5.78B |
$4.21B |
1.37 |
| 1993-03-31 |
$5.24B |
$4.45B |
1.18 |
| 1992-12-31 |
$4.87B |
$4.72B |
1.03 |
| 1992-09-30 |
$4.63B |
$5.47B |
0.85 |
| 1992-06-30 |
$4.49B |
$5.03B |
0.89 |
| 1992-03-31 |
$4.37B |
$5.06B |
0.86 |
| 1991-12-31 |
$4.57B |
$5.03B |
0.91 |
| 1991-09-30 |
$3.91B |
$5.07B |
0.77 |
| 1991-06-30 |
$3.97B |
$4.83B |
0.82 |
| 1991-03-31 |
$3.61B |
$5.18B |
0.70 |
| 1990-12-31 |
$3.96B |
$5.09B |
0.78 |
| 1990-09-30 |
$3.49B |
$5.01B |
0.70 |
| 1990-06-30 |
$3.39B |
$4.68B |
0.73 |
| 1990-03-31 |
$3.19B |
$4.74B |
0.67 |
| 1989-12-31 |
$3.79B |
$4.54B |
0.84 |
| 1989-09-30 |
$3.18B |
$4.53B |
0.70 |
| 1989-06-30 |
$3.32B |
$4.31B |
0.77 |
| 1989-03-31 |
$3.09B |
$4.48B |
0.69 |
| 1988-12-31 |
$0.36B |
$4.30B |
0.08 |
| 1988-09-30 |
$3.03B |
$4.25B |
0.71 |
| 1988-06-30 |
$3.06B |
$4.13B |
0.74 |
| 1988-03-31 |
$2.91B |
$4.04B |
0.72 |
| 1987-12-31 |
$3.02B |
$3.88B |
0.78 |
| 1987-09-30 |
$2.03B |
$3.78B |
0.54 |
| 1987-06-30 |
$2.05B |
$3.64B |
0.56 |
| 1987-03-31 |
$1.79B |
$3.58B |
0.50 |
| 1986-12-31 |
$1.79B |
$3.42B |
0.52 |
| 1985-12-31 |
$1.50B |
$2.93B |
0.51 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
